Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202). |
| Type de publication | Journal Article |
| Year of Publication | 2019 |
| Auteurs | Coleman M, Belada D, Casasnovas R-O, Gressin R, Lee H-P, Mehta A, Munoz J, Verhoef G, Corrado C, DeMarini DJames, Zhao W, Chen X, Fay K |
| Journal | JOURNAL OF CLINICAL ONCOLOGY |
| Volume | 37 |
| Date Published | MAY 20 |
| Type of Article | Meeting Abstract |
| ISSN | 0732-183X |